Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
RFK Jr. wants to scrutinize the vaccine schedule – but its safety record is already decades long - 2'Women on the floor, riddled with bullets': Ex-hostage Rom Braslavski recounts 'horrors' of Oct. 7
- 3She's been a Bond girl and a mutant. Now she's grappling with Hollywood's obsession with 'eternal youth.'
- 4A Timeline of Rising Antisemitism in Australia
- 5Herzog, German Chancellor Merz discuss final Gaza hostage, Arrow 3 exchange in Jerusalem
- Manual for Wonderful Getaway destination
- Shredded cheese sold in dozens of states recalled due to potential for metal fragment contamination
- The Craft of Do-It-Yourself Home Stylistic layout: Change Your Space
- Vote in favor of your Favored sort of footwear
- Native artists in Texas and Mexico shared their vision of the universe for 4,000 years, ancient murals suggest
- Scientists map of old Mars river basins for the 1st time. These could be great places to search for ancient life
- Vaccine makers raise concerns over US panel's shift away from hepatitis B shots for newborns
- Figure out How to Put resources into Lab Precious stones
- Vote in favor of Your #1 Climbing boots Now
